UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Early Mortality Risk with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1,336 Patients from MRC/NCRI and SWOG

Leukemia & lymphoma, 2022-10, Vol.64 (1), p.250-252

2022

Volltextzugriff (PDF)

Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway

Leukemia, 2017-05, Vol.31 (5), p.1154-1165

2017

Volltextzugriff (PDF)

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

Blood, 2013-11, Vol.122 (20), p.3432-3439

2013

Volltextzugriff (PDF)

Heckathorn disease revisited

Blood, 2014-02, Vol.123 (9), p.1429-1431

2014

Volltextzugriff (PDF)

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

Leukemia & lymphoma, 2023-01, Vol.64 (1), p.250-252

2023

Volltextzugriff (PDF)

Increased Risk of Sternal Complications in Patients with Plasma Cell Dyscrasias (PCDs) Undergoing Coronary Artery Bypass Graft (CABG)

Blood, 2015-12, Vol.126 (23), p.5319-5319

2015

Volltextzugriff (PDF)

Prevalence of Multiple Primary Hematologic Malignancies Seen at a Tertiary Care Center

Blood, 2015-12, Vol.126 (23), p.5017-5017

2015

Volltextzugriff (PDF)

Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival

Blood, 2016-12, Vol.128 (22), p.1613-1613

2016

Volltextzugriff (PDF)

Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling

Oncotarget, 2017-01, Vol.8 (5), p.8420-8435

2017

Volltextzugriff (PDF)

Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.3979-3979

2018

Volltextzugriff (PDF)

Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia

Leukemia & lymphoma, 2020-07, Vol.61 (8), p.1965-1973

2020

Volltextzugriff (PDF)

Anaplastic large-cell lymphoma (ALK-negative)-related heart failure and recurrence after heart transplantation

The Journal of heart and lung transplantation, 2020-10, Vol.39 (10), p.1156-1158

2020

Volltextzugriff (PDF)

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

Blood, 2016-12, Vol.128 (22), p.4002-4002

2016

Volltextzugriff (PDF)

Hirudin therapy for heparin‐associated thrombocytopenia and deep venous thrombosis

American journal of hematology, 1993-08, Vol.43 (4), p.310-311

Nand, Sucha

1993

Volltextzugriff (PDF)

Limitations of Performance Status (PS) Assignment in Predicting Outcomes of Acute Myeloid Leukemia (AML) and the Role of Objective Parameters in Predicting PS Assignment

Blood, 2011-11, Vol.118 (21), p.4191-4191

2011

Volltextzugriff (PDF)

Germ-Line and Somatic Mutations in Familial Myeloproliferative Neoplasms (MPNs). a Pilot Study

Blood, 2014-12, Vol.124 (21), p.3214-3214

2014

Volltextzugriff (PDF)

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

Leukemia & lymphoma, 2008-01, Vol.49 (11), p.2141-2147

2008

Volltextzugriff (PDF)

Association between early promoter methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT0065884)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7060-7060

2015

Volltextzugriff (PDF)

Blast crisis in chronic myelogenous leukemia remains a difficult therapeutic challenge

Leukemia & lymphoma, 2007-02, Vol.48 (2), p.215-216

2007

Volltextzugriff (PDF)

Sensitizing Leukemic Cells to NF-κB Inhibitor Treatment by Repressing TNFα-Mediated, NF-κB-Independent Survival Signaling

Blood, 2012-11, Vol.120 (21), p.1878-1878

2012

Volltextzugriff (PDF)

Sensitizing Acute Myeloid Leukemia Cells to Interferon-Induced Differentiation By Inhibiting RIP1/RIP3 Necroptotic Pathway

Blood, 2014-12, Vol.124 (21), p.3752-3752

2014

Volltextzugriff (PDF)

Title: Promoter Methylation of Selected Genes and Response to Azacitidine (AZ) Therapy in Patients with Non-BCR-ABL Myeloproliferative Disorders (MPDs)

Blood, 2011-11, Vol.118 (21), p.4625-4625

2011

Volltextzugriff (PDF)

Pulmonary hypertension in polycythemia vera

American journal of hematology, 1994-11, Vol.47 (3), p.242-244

1994

Volltextzugriff (PDF)

Anemias excluding cobalamin and folate deficiencies

Handbook of Clinical Neurology, 2014, Vol.120, p.1005-1014

2014

Volltextzugriff (PDF)

26 – 50 von 106

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(92)

Publikationsform

Sprache

Englisch
(106)

Erscheinungsjahr

n.n

Thema

Humans
(59)
Life Sciences & Biomedicine
(53)
Science & Technology
(53)
Hematology
(32)
Female
(24)
Biological And Medical Sciences
(23)
Medical Sciences
(23)
Middle Aged
(23)
Male
(20)
Oncology
(14)
Aged
(13)
Adult
(10)
Pharmacology. Drug Treatments
(10)
Acute Myeloid Leukemia
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Leukemia, Myeloid, Acute - Drug Therapy
(7)
Risk Factors
(7)
Aged, 80 And Over
(6)
Hematologic And Hematopoietic Diseases
(6)
Anemia
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Early Mortality Risk with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1,336 Patients from MRC/NCRI and SWOG

Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

Heckathorn disease revisited

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

Increased Risk of Sternal Complications in Patients with Plasma Cell Dyscrasias (PCDs) Undergoing Coronary Artery Bypass Graft (CABG)

Prevalence of Multiple Primary Hematologic Malignancies Seen at a Tertiary Care Center

Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival

Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling

Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia

Anaplastic large-cell lymphoma (ALK-negative)-related heart failure and recurrence after heart transplantation

Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

Hirudin therapy for heparin‐associated thrombocytopenia and deep venous thrombosis

Limitations of Performance Status (PS) Assignment in Predicting Outcomes of Acute Myeloid Leukemia (AML) and the Role of Objective Parameters in Predicting PS Assignment

Germ-Line and Somatic Mutations in Familial Myeloproliferative Neoplasms (MPNs). a Pilot Study

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

Association between early promoter methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT0065884)

Blast crisis in chronic myelogenous leukemia remains a difficult therapeutic challenge

Sensitizing Leukemic Cells to NF-κB Inhibitor Treatment by Repressing TNFα-Mediated, NF-κB-Independent Survival Signaling

Sensitizing Acute Myeloid Leukemia Cells to Interferon-Induced Differentiation By Inhibiting RIP1/RIP3 Necroptotic Pathway

Title: Promoter Methylation of Selected Genes and Response to Azacitidine (AZ) Therapy in Patients with Non-BCR-ABL Myeloproliferative Disorders (MPDs)

Pulmonary hypertension in polycythemia vera

Anemias excluding cobalamin and folate deficiencies

Suchergebnisse filtern